Close
Important notice regarding Brexit for researchers who are PIs and CIs on 果冻影院H Clinical Trials
14 October 2019
The UK is due to leave the EU on the 31 October 2019. Regardless of whether there is a deal or no-deal Brexit, there are actions Chief Investigators and Principal Investigators need to take.
Urgent actions before 31 October
Planning for any disruption to the supply of equipment, samples or drugs to research studies should have been sent to PIs and CIs by the trial sponsor.
PIs and CIs who have yet to receive an adequate assurance of the above should make immediate contact with the research sponsor. This is particularly the case for studies reliant on IMP (Investigational Medicinal Products) or other drugs, specialist equipment or products which are supplied outside of the UK. The PI or CI should also have been provided with instructions or guidance specific to their research study.
Several sponsors have provided general assurances to 果冻影院H (either to 果冻影院H Pharmacy or 果冻影院H R&D); a list of these sponsors available upon request from 果冻影院H R&D.
Actions after 31 October
If Brexit results in any unforeseen issues (i.e., outside of sponsor contingency plans) that impacts the delivery of the trial at 果冻影院H, the 果冻影院H CI or PI must immediately contact the research sponsor and in the case of IMP, 果冻影院H Pharmacy.聽
Any queries should be sent to jro.communications@nhs.net
The JRO has separately put together a position statement in relation to clinical trials sponsored by 果冻影院 in the event of a 鈥榥o deal鈥� Brexit.